SLGL (Sol-Gel Technologies) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SLGL Sol-Gel Technologies Ltd SLGL
55 GF Score
Price $83.20
GF Value $66.10
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Sol-Gel Technologies Short-term investments?

Short-term investments only applies to insurance companies.

SLGL
55GF Score
Sol-Gel Technologies Ltd SLGL
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sol-Gel Technologies (SLGL) Overvalued in 2026?

Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued. The current stock price of $83.20 is trading 25.9% above its estimated GF Value™ of $66.10. GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.

Key valuation signals for SLGL:

  • Short-term investments:
  • GF Value™: $66.10 vs. price of $83.20 (25.9% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the SLGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sol-Gel Technologies Business Description

Other Exchanges 4SG:Germany
Address 7 Golda Meir Street, Weizmann Science Park, Ness Ziona, ISR, 7403650
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score

Get the complete analysis for SLGL

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$83.20
Price
$66.10
GF Value